Financial Daily from THE HINDU group of publications
Saturday, Mar 01, 2003

Port Info

Group Sites

Industry & Economy - Pharmaceuticals

Budget breathes new life into pharmaceuticals sector

Our Bureau

NEW DELHI, Feb. 28

IT is being hailed as the "best budget" that the pharma industry has seen in the last few years — not just because it has been favourable to the industry, but more importantly, it has been kind to consumers.

With life-saving drugs being exempted from both excise and customs duty, the benefits would definitely be passed on to the consumers, opine top-brass of the pharma industry.

Mr Rajiv Gulati, Managing Director of Eli Lilly in India, told Business Line that more clinical trials and research-based investments would be brought into India by MNC-pharma companies, thanks to the Budget's waiver on clinical trial equipment. He said that the budget was balanced in its approach towards both domestic and foreign pharma companies. ``In clinical research, the finance Minister has waived customs as well as excise and so is the case with life-saving drugs. The net-result is that patients will gain, as these benefits would be passed on to the consumer.''

The Budget has benefited the country, as more research would now be done here and more funds would come in, as a result. Mr Gulati was also happy with the direction that the Budget took, in terms of ``health insurance, medical infrastructure and steps to take these facilities to the disadvantaged.''

Mr Ajay Vij, Vice-President (Pharmaceuticals), Dabur Pharmaceuticals, welcomed the excise exemptions on life-saving drugs, but pointed out that the scope of this list of drugs should have been widened. ``Increase in the overall limit for overseas investments, from 50 per cent of net worth to 100 per cent, through the automatic route is a favourable development for opening up subsidiaries abroad," he observed. "Customs duty reduction in import of medical equipment would, over a time span, improve the health facilities in the country and make treatment more affordable," he added.

Mr D.G.Shah of the Indian Pharmaceutical Alliance also felt that the Budget was balanced in its approach to both the domestic and MNC pharma companies.

Striking a different note, Ranbaxy's Senior Vice-President, Mr B.K. Raizada said the Budget had ``no impact'' on his company. ``We are an outward looking company and the Budget was silent on companies with operations in international markets and those who take their research abroad, in terms of filing patents in international markets. We should be treated on par with infotech companies for the investments on intellectual property in global markets, the income from which would be ploughed back in research in the domestic market.''

Further, he pointed out that the Budget was kind to MNCs doing business in India and affiliates of foreign companies, ``who are increasing importing products into the country and producing less here.'' Unhappy with the Budget for ``allowing access to the domestic market, while not encouraging outward looking countries'' he said : ``Regulatory costs in India are seen as expenditure, but income from export of R&D work is not exempted.''

Industry analysts point out that Novartis, with a pipeline of cancer-related and life-saving products, Eli Lilly, Astra Zeneca and GlaxoSmithKline are some of the companies that would benefit from the Budget. Novartis also manufactures Cyclosporine, another life-saving drug, which was singled out for excise duty exemption.

Article E-Mail :: Comment :: Syndication

Stories in this Section
Time to invest in equity, debt

Riding the break
Jaswant smiles on the salaried
Impetus and impediments
Dividend, tax gains for MF investors
CST cut to hurt States by Rs 5,000 cr
Style & substance true to form
Will Mauritius lose its sheen?
A curate's egg
That Black Label may cost you less!
Women give the thumbs-up
Prices falling? Just read the fine print
Rly safety gets customs boost
Addl surcharge: No major impact
Health cover for the masses
Hope for disability sector
Jaswant nurtures biotech dreams
An oversight for plastic lens manufacturers?
`A boost for infrastructure'
`Small & simple' Ministry
Cement: An excise load
Many pluses, 1 minus
Good news for cement sector
`Hike in excise duty on cement unnecessary'
Cement industry sore over hike in excise duty
How much do we really owe?
Jaswant packs panch punch to push reforms
Engineering: Increase in service tax
Gold duty cut to beat down smuggling
Fertilisers: Bracing up
Urea price hike not to benefit fertiliser cos
Differing views on risks posed by asbestos use
A five-star plan
Want better roads? Pay 50 paise more for diesel, petrol
45 pc hike in kerosene, LPG subsidy
Big disappointment on oil front
ONGC signs pact with IOC to sell crude
Rs 3,600 cr more from petro sector likely
Budget breathes new life into pharmaceuticals sector
Booster dose for drugs
Pharma sector hails sops
Lower customs duty on equipment hailed — Easing of policy unlikely to lead to new power projects
Steel sector sees silver lining
Signals were clear on Kelkar
`Duty retention on cotton yarn welcome move'
SIMA hails abolition of `deemed' credit
Textile wears a smiling look
SSI list pruned further
Tyre cos hope for more sales mileage
Buoyant coal outlook calls for more pvt hands
Look great and feel good
Price cuts drive auto into top gear
Car makers upbeat about sales volumes
Towards a cycle of development
Toyota to cut price; Volvo may not
Smooth road ahead for car companies
Excise cut to fizzle out on soft drink prices
Gem sector finds hope
Good news for the sick
More benefits for health care
Small paper mills in excise trap
Chennai port has been neglected: SICCI
Keep that shirt on, prices are not going to fall
Knitters decry Cenvat net
Mining units unhappy
Govt hopeful of meeting disinvestment target
Hoping on big-ticket divestments
Disinvestment target fixed at Rs 13,200 cr
Small savings: Remain beneficial for common man
A dividend sop and an unkind cut
Jaswant leaves more money in salaried pocket
Dividend tax, capital gains tax to go — Capital markets get a lift
Dividend tax removal — Promoters, high tax payers to be major beneficiaries
Will purse bear burden or bulge?
Budget vs the professional CA
`A leg-up' for tourism trade

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | Home |

Copyright 2003, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line